Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm : conditioning intensity matters. / Bruch, Peter Martin; Dietrich, Sascha; Finel, Herve; Boumendil, Ariane; Greinix, Hildegard; Heinicke, Thomas; Bethge, Wolfgang; Beelen, Dietrich; Schmid, Christoph; Martin, Hans; Castagna, Luca; Scheid, Christof; Schäfer-Eckart, Kerstin; Bittenbring, Jörg; Finke, Jürgen; Sengeloev, Henrik; Heiblig, Mael; Cornelissen, Jan; Chevallier, Patrice; Mohty, Mohamad; Robinson, Stephen; Montoto, Silvia; Dreger, Peter.
I: Leukemia, Bind 37, Nr. 2, 2023, s. 465-472.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm
T2 - conditioning intensity matters
AU - Bruch, Peter Martin
AU - Dietrich, Sascha
AU - Finel, Herve
AU - Boumendil, Ariane
AU - Greinix, Hildegard
AU - Heinicke, Thomas
AU - Bethge, Wolfgang
AU - Beelen, Dietrich
AU - Schmid, Christoph
AU - Martin, Hans
AU - Castagna, Luca
AU - Scheid, Christof
AU - Schäfer-Eckart, Kerstin
AU - Bittenbring, Jörg
AU - Finke, Jürgen
AU - Sengeloev, Henrik
AU - Heiblig, Mael
AU - Cornelissen, Jan
AU - Chevallier, Patrice
AU - Mohty, Mohamad
AU - Robinson, Stephen
AU - Montoto, Silvia
AU - Dreger, Peter
N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023
Y1 - 2023
N2 - Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, the individual contributions of conditioning and graft-versus-tumor (GVT) effects to HCT success are undefined. We present a retrospective study of 162 adult patients who underwent a first HCT (allogeneic 146, autologous 16) between 2009 and 2017, and were registered with the EBMT. Median age was 57 (range 20–73) years, and disease status at HCT was first complete remission (CR1) in 78%. Among patients receiving allogeneic HCT (alloHCT), myeloablative conditioning (MAC), reduced intensity conditioning (RIC) and in-vivo T-cell depletion (TCD) were used in 54%, 46%, and 59% respectively. Total body irradiation (TBI) was the conditioning backbone in 61% of MAC and 26% of RIC transplants. One-year overall survival (OS) and progression-free survival (PFS) rates were comparable after alloHCT and autologous HCT (autoHCT). Among alloHCT recipients, MAC with TBI significantly improved OS and PFS, independently of CR1, age, Karnofsky index and TCD. Accordingly, MAC (ideally based on TBI) should be preferred for alloHCT recipients with BPDCN. In patients who are not elegible for MAC alloHCT, autoHCT could be considered.
AB - Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, the individual contributions of conditioning and graft-versus-tumor (GVT) effects to HCT success are undefined. We present a retrospective study of 162 adult patients who underwent a first HCT (allogeneic 146, autologous 16) between 2009 and 2017, and were registered with the EBMT. Median age was 57 (range 20–73) years, and disease status at HCT was first complete remission (CR1) in 78%. Among patients receiving allogeneic HCT (alloHCT), myeloablative conditioning (MAC), reduced intensity conditioning (RIC) and in-vivo T-cell depletion (TCD) were used in 54%, 46%, and 59% respectively. Total body irradiation (TBI) was the conditioning backbone in 61% of MAC and 26% of RIC transplants. One-year overall survival (OS) and progression-free survival (PFS) rates were comparable after alloHCT and autologous HCT (autoHCT). Among alloHCT recipients, MAC with TBI significantly improved OS and PFS, independently of CR1, age, Karnofsky index and TCD. Accordingly, MAC (ideally based on TBI) should be preferred for alloHCT recipients with BPDCN. In patients who are not elegible for MAC alloHCT, autoHCT could be considered.
U2 - 10.1038/s41375-022-01782-z
DO - 10.1038/s41375-022-01782-z
M3 - Journal article
C2 - 36550212
AN - SCOPUS:85144538592
VL - 37
SP - 465
EP - 472
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 2
ER -
ID: 397795074